Trial reportRespiratory research2017
Serum bilirubin and the risk of chronic obstructive pulmonary disease exacerbations.
Trial report in Respiratory research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Chronic Macrolide Administration on the Frequency and Severity of COPD Exacerbations
Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Serum bilirubin and chronic obstructive pulmonary disease (COPD): a systematic review.BMC pulmonary medicine · 2021Pooled it
- Association Between Pulmonary Function, Respiratory Muscle Strength and Cognitive Function in Chinese Community-Dwelling Older Adults.Clinical interventions in aging · 2026Article
- A predictive model for frequent exacerbator phenotype of acute exacerbations of chronic obstructive pulmonary disease.Journal of thoracic disease · 2023Article
- Bilirubin-associated single nucleotide polymorphism (SNP) and respiratory health outcomes: a mendelian randomization study.Respiratory research · 2023Article
- Circulating liver function markers and the risk of COPD in the UK Biobank.Frontiers in endocrinology · 2023Article
- Association Between Serum Total Bilirubin and COPD: Results from a Cross-Sectional Study and a Bidirectional Mendelian Randomization Analysis.Clinical epidemiology · 2022Article
- Association Between Serum Total Bilirubin Level and Lung Function Decline in Patients with COPD: Results from a Pooled Study.International journal of chronic obstructive pulmonary disease · 2022Observational
- Candidate gene prioritization for chronic obstructive pulmonary disease using expression information in protein-protein interaction networks.BMC pulmonary medicine · 2021Article
- Plasma Metabolomic Signatures of Chronic Obstructive Pulmonary Disease and the Impact of Genetic Variants on Phenotype-Driven Modules.Network and systems medicine · 2020Article
- Serum bilirubin level is associated with exercise capacity and quality of life in chronic obstructive pulmonary disease.Respiratory research · 2019Article
- Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers.Molecular diagnosis & therapy · 2019Review
- FKBP5 rs4713916: A Potential Genetic Predictor of Interindividual Different Response to Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease in a Real-Life Setting.International journal of molecular sciences · 2019Article
- Association of serum bilirubin level with lung function decline: a Korean community-based cohort study.Respiratory research · 2018Article
- Correlation between serum bilirubin levels and the severity as well as the prognosis of idiopathic pulmonary fibrosis.Chronic respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundBilirubin is a potent anti-oxidant and higher serum concentrations of bilirubin have been associated with better lung function, slower lung function decline, and lower incidence of chronic obstructive pulmonary disease (COPD). We sought to determine whether elevated bilirubin blood concentrations are associated with lower risk for acute exacerbations of COPD (AECOPD).
methodsWe performed a secondary analyses of data in the Simvastatin for Prevention of Exacerbations in Moderate-to-Severe COPD (STATCOPE) and the Azithromycin for Prevention of Exacerbations of COPD (MACRO) studies. We used time-dependent multivariable Cox proportional hazards analyses, using bilirubin concentrations prior to first AECOPD as the exposure variable and time to first AECOPD as the outcome variable. STATCOPE was used for model development, with validation in MACRO.
resultsIn STATCOPE (n = 853), higher bilirubin was associated with a lower but statistically insignificant hazard for AECOPD, (adjusted hazard ratio [aHR] 0.89 per log
conclusionsBilirubin may be a biomarker of AECOPD risk and may be a novel therapeutic target to reduce AECOPD risk. TRIAL REGISTRATIONS: ClinicalTrials.gov NCT01061671 (registered 02 February 2010) and ClinicalTrials.gov NCT00325897 (registered 12 May 2006).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.